Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity

Journal of Virology

Volumn 73, Issue 1, 1999, Pages 519-532

  Goins, William F ^a   Lee, Kevin A ^a   Cavalcoli, James D ^a   O'Malley, Mark E ^b   Dekosky, Steven T ^b   Fink, David J ^a,c   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HYDROGEN PEROXIDE; NERVE GROWTH FACTOR; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; GENE EXPRESSION; GENE TRANSFER; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; SPINAL GANGLION; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0032889563     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.1.519-532.1999     Document Type: Article

References (14)

1. Anand, P., G. Terenghi, G. Warner, P. Kopelman, R. E. Williams-Chestnut, and D. V. Sinicropi. 1996. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat. Med. 2:703-707.
2. Apfel, S. C., J. C. Arezzo, M. Brownlee, H. Federoff, and J. A. Kessler. 1994. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 634:7-12.
3. Apfel, S. C., J. C. Arezzo, L. Lipson, and J. A. Kessler. 1992. Nerve growth factor prevents experimental cisplatin neuropathy. Ann. Neurol. 31:76-80.
4. Apfel, S. C., and J. A. Kessler. 1995. Neurotrophic factors in the therapy of peripheral neuropathy. Baillieres Clin. Neurol. 4:593-606.
5. Batchelor, A. H., and P. O. O'Hare. 1990. Regulation and cell-type-specific activity of a promoter located upstream of the latency-associated transcript of herpes simplex virus type 1. J. Virol. 64:3269-3279.
6. Baumgartner, B., and H. Shine. 1997. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. J. Neurosci. 17:6504-6511.
7. Bilang-Bleuel, A., F. Reran, P. Colin, I. Locquet, J.-J. Robert, J. Mallet, and P. Horellou. 1997. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 94:8818-8823.
8. Block, T., S. M. Barney, J., J. Maggioncalda, T. Valyi-Nagy, and N. W. Fraser. 1994. Long term herpes simplex virus type 1 infection of nerve growth factor-treated PC12 cells. J. Gen. Virol. 75:2481-2487.
9. Butcher, L. L., and N. J. Woolf. 1989. Neurotrophic agents may exacerbate the pathologic cascade of Alzheimer's disease. Neurobiol. Aging 10:557-570.
10. Cedarbaum, J. M., and N. Stambler. 1997. Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials. J. Neurol. Sci. 152:S1-S9.
11. Chen, X., M. C. Schmidt, W. F. Coins, and J. C. Glorioso. 1995. Two herpes simplex virus type-1 latency active promoters differ in their contribution to latency-associated transcript expression during lytic and latent infection. J. Virol. 69:7899-7908.
12. Choi-Lundberg, D., Q. Lin, Y.-N. Chang, Y.-L. Chiang, C. Hay, H. Mohajeri, B. Davidson, and M. Bohn. 1996. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275:838-841.
13. Clegg, D. O. 1993. Characterization of a beta-nerve growth factor expression vector for mammalian cells. Gene 25:291-296.
14. Clements, G. B., and P. G. E. Kennedy. 1989. Modulation of herpes simplex virus (HSV) infection of cultured neuronal cells by nerve growth factor and antibody to HSV. Brain 112:1277-1294.